2024-05-14 16:43:02 ET
Amgen Inc. (AMGN)
BofA Securities 2024 Health Care Conference
May 14, 2024 12:20 AM ET
Company Participants
Peter Griffith - EVP & CFO
James Bradner - EVP, Research and Development & Chief Scientific Officer
Justin Claeys - VP, IR
Conference Call Participants
Geoff Meacham - BofA Securities
Presentation
Peter Griffith
[Call Starts Abruptly] for the Phase II study is complete and that we are confident in MariTide's differentiated profile and are actively planning a broad Phase 3 program, including obesity, obesity-related conditions, and diabetes. We've also initiated activities to further expand manufacturing capacity with both clinical and commercial supply in mind. We had a chance to meet with investors following the earnings call. We were asked an important question. How do we view the business beyond obesity?
In short, we've got great confidence we're on a path to deliver attractive long-term growth through the end of the decade and beyond. Not just because of obesity, but rather from the breadth and the depth of our four therapeutic areas, general medicine, oncology, inflammation, and rare disease, each of which have strong momentum and plenty of room to grow.
In terms of marketed products, let's recap. Repatha in the first quarter, up 33%, 44% volume growth. EVENITY was up 35% in the bone franchise. BLINCYTO, acute lymphoblastic leukemia, very important medicine, up 26%. TEZSPIRE treating severe asthma 80%. With BLINCYTO, we expect an approval in June, June 21st PDUFA date that should accelerate our efforts to integrate into earlier lines for acute lymphoblastic leukemia. With test fire, we'll share encouraging data later this month that reflect the attractive potential of the medicine in chronic obstructive pulmonary disease, where new treatments are very much needed....
Read the full article on Seeking Alpha
For further details see:
Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)